Education
About Us
Working with TipRanks
Follow Us
Luxbright AB (SE:LXB)
:LXB
Top Page
Luxbright AB
(Frankfurt:LXB)
39Underperform
Luxbright AB (LXB) vs. S&P 500 (SPY)
Market Cap
€81.14M
Dividend YieldN/A
Average Volume (3M)39.41K
Price to Earnings (P/E)―
Beta (1Y)>-0.01
Revenue Growth955.20%
EPS Growth47.31%
CountrySE
Employees12
SectorHealthcare
Sector Strength65
IndustryMedical Equipment & Supplies
Share Statistics
EPS (TTM)-0.17
Shares Outstanding112,687,700
10 Day Avg. Volume28,668
30 Day Avg. Volume39,410
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Luxbright AB Business Overview & Revenue Model
Company DescriptionLuxbright AB (LXB) is a Sweden-based company that operates in the medical technology sector. The company specializes in the development and manufacturing of innovative X-ray tubes and generators, which are utilized in various applications including healthcare, security, and industrial inspection. Luxbright is dedicated to advancing X-ray technology with its proprietary cold cathode technology, which aims to enhance image quality and reduce radiation exposure.
How the Company Makes MoneyLuxbright AB generates revenue by designing, producing, and selling its advanced X-ray tubes and systems to clients in the healthcare, security, and industrial sectors. The company capitalizes on its unique cold cathode technology, which offers enhanced performance and safety features compared to traditional X-ray systems, attracting a variety of customers looking for cutting-edge solutions. Luxbright may also form strategic partnerships or licensing agreements to expand its market reach and further monetize its proprietary technology. Additionally, the company might receive income from research collaborations and grants aimed at advancing its technological innovations.
Luxbright AB Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 5.53M | 9.02M | 854.70K | 811.70K | 729.00K | 614.29K | Gross Profit |
| -9.43M | 8.88M | -2.80M | 189.12K | 1.98M | 1.57M | EBIT |
| -22.88M | -18.06M | -25.80M | -21.52M | -17.91M | -12.29M | EBITDA |
| -20.20M | -15.72M | -24.35M | -20.47M | -17.63M | -12.18M | Net Income Common Stockholders |
| -22.23M | -17.72M | -25.38M | -21.13M | -18.10M | -12.47M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 6.34M | 12.36M | 14.04M | 7.60M | 7.51M | 29.51M | Total Assets |
| 15.44M | 42.66M | 40.69M | 31.19M | 23.99M | 44.11M | Total Debt |
| 2.06M | 0.00 | 206.02K | 588.34K | 1.10M | 1.81M | Net Debt |
| -4.27M | -12.36M | -13.83M | -7.01M | -6.41M | -27.71M | Total Liabilities |
| 4.94M | 8.46M | 7.00M | 3.33M | 3.36M | 5.47M | Stockholders Equity |
| 10.50M | 34.20M | 33.69M | 27.86M | 20.63M | 38.64M |
| Cash Flow | Free Cash Flow | ||||
| -16.27M | -16.52M | -20.39M | -20.64M | -17.14M | -13.67M | Operating Cash Flow |
| -16.27M | -16.52M | -20.39M | -20.64M | -17.14M | -13.67M | Investing Cash Flow |
| -4.38M | -3.44M | -3.99M | -7.15M | -4.15M | -3.42M | Financing Cash Flow |
| -425.00K | 18.28M | 30.82M | 27.88M | -708.00K | 40.26M |
Luxbright AB Technical Analysis
Negative
0.72
Price Trends
0.77
Negative
0.80
Negative
0.88
Negative
Market Momentum
>-0.01
Positive
47.76
Neutral
76.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:LXB, the sentiment is Negative. The current price of 0.72 is below the 20-day moving average (MA) of 0.79, below the 50-day MA of 0.77, and below the 200-day MA of 0.88, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 47.76 is Neutral, neither overbought nor oversold. The STOCH value of 76.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:LXB.
Luxbright AB Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | kr10.22M | ― | ― | 96.10% | 94.79% | ||
51 Neutral | $5.31B | 3.33 | -39.82% | 2.92% | 17.95% | 1.84% | |
39 Underperform | €81.14M | ― | -51.52% | ― | 955.20% | 47.31% | |
33 Underperform | kr25.16M | ― | ― | -63.52% | 93.00% | ||
28 Underperform | kr60.40M | ― | -82.35% | ― | 127.04% | 92.31% | |
23 Underperform | €212.61M | ― | -159.24% | ― | -22.50% | 76.74% |
* Healthcare Sector Average
Performance Comparison
SE:LXB
Luxbright AB
0.77
-0.21
-21.43%
SE:CLS.B
Clinical Laserthermia Systems AB Class B
3.00
-13.56
-81.90%
SE:QLIFE
Qlife Holding AB
2.03
0.67
49.59%
SE:QLINEA
Q-linea AB
0.04
-0.43
-91.85%
SE:S2M
S2Medical AB Class B
0.01
-0.06
-83.78%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.